Both CD8+ and CD4+T cells can mount responses against many human cancer types, especially those with higher mutational burden (3, 27) and several studies in different tumour types have shown a correlation between tumor-infiltrating effector CD8+ T cells and favorable clinical outcomes (1) (28). The gene discussed is CD8A; the disease is cancer.